Skip to main content
SpringerLink
Log in

Immunosuppression for interstitial lung disease in systemic sclerosis – novel insights and opportunities for translational research

  • Commentary
  • Published:
Journal of Cell Communication and Signaling Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Assassi S, Sharif R et al (2010) Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 12(5):R166

    Article  PubMed  Google Scholar 

  • Barnett AJ (1978) Scleroderma (progressive systemic sclerosis): progress and course based on a personal series of 118 cases. Med J Aust 2(4):129–134

    PubMed  CAS  Google Scholar 

  • Chifflot H, Fautrel B et al (2008) Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 37:223–235

    Article  PubMed  Google Scholar 

  • Choi HK, Hernan MA et al (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359(9313):1173–1177

    Article  PubMed  CAS  Google Scholar 

  • Clements PJ (1995) Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 7(6):517–521

    Article  PubMed  CAS  Google Scholar 

  • Cotter D, Zhang Y et al (2008) The effect of epoetin dose on hematocrit. Kidney Int 73(3):347–353

    Article  PubMed  CAS  Google Scholar 

  • Goh NS, Desai SR et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254

    Article  PubMed  Google Scholar 

  • Greidinger EL, Flaherty KT et al (1998). “African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.” 114:801–807

  • Hernán M, Brumback B et al (2001) Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc 96(454):440–448

    Article  Google Scholar 

  • Hernan MA, Brumback BA et al (2002) Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 21(12):1689–1709

    Article  PubMed  Google Scholar 

  • Hoyles RK, Ellis RW et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970

    Article  PubMed  CAS  Google Scholar 

  • Hudson M, Baron M et al (2011) Observational data to study medication outcomes in systemic sclerosis. J Rheumatol 38(3):575–577

    Article  PubMed  Google Scholar 

  • MacKenzie EJ, Rivara FP et al (2006) A national evaluation of the effect of trauma-center care on mortality. N Engl J Med 354(4):366–378

    Article  PubMed  CAS  Google Scholar 

  • Palella FJ Jr, Armon C et al (2009) The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med 151(2):73–84

    PubMed  Google Scholar 

  • Plastiras SC, Karadimitrakis SP et al (2006) Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 55(4):598–602

    Article  PubMed  Google Scholar 

  • Rawlins M (2008) De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 372(9656):2152–2161

    Article  PubMed  Google Scholar 

  • Roth MD, Tseng CH et al (2011) Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 63(9):2797–2808

    Article  PubMed  Google Scholar 

  • Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127(8 Pt 2):757–763

    PubMed  CAS  Google Scholar 

  • Steele R, Hudson M et al (2011) A clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 64(4):519–524

    Article  Google Scholar 

  • Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66(7):940–944

    Article  PubMed  Google Scholar 

  • Steen VD, Owens GR et al (1985) The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 28(8):882–888

    Article  PubMed  CAS  Google Scholar 

  • Steen VD, Conte C et al (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37(9):1283–1289

    Article  PubMed  CAS  Google Scholar 

  • Sterne JA, Hernan MA et al (2005) Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366(9483):378–384

    Article  PubMed  CAS  Google Scholar 

  • Tashkin DP, Elashoff R et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666

    Article  PubMed  CAS  Google Scholar 

  • White B (2003) Interstitial lung disease in scleroderma. Rheum Dis Clin N Am 29(2):371–390

    Article  Google Scholar 

Download references

Funding

This study was funded in part by the Canadian Institutes of Health Research, the Scleroderma Society of Canada and educational grants from Actelion Pharmaceuticals and Pfizer Inc. Dr. Hudson is supported by a Chercheur-clinicien boursier award from the Fonds de la Recherche en Santé du Québec. The funding sources had no role in the design of the study, analysis of the data, preparation of the manuscript and decision to submit for publication.

Author information

Authors and Affiliations

  1. Jewish General Hospital, Lady Davis Institute for Medical Research and McGill University, Montreal, QC, Canada

    Marie Hudson, Russell Steele & Murray Baron

  2. Jewish General Hospital, Room A-725, 3755 Cote Ste Catherine Road, Montreal, Quebec, H3T 1E2, Canada

    Marie Hudson

Authors
  1. Marie Hudson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell Steele
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Murray Baron
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Canadian Scleroderma Research Group

Corresponding author

Correspondence to Marie Hudson.

Additional information

Investigators of the Canadian Scleroderma Research Group: M. Baron, Montreal, Quebec; J. Pope, London, Ontario; J. Markland, Saskatoon, Saskatchewan; D. Robinson, Winnipeg, Manitoba; N. Jones, Edmonton, Alberta; N. Khalidi, Hamilton, Ontario; P. Docherty, Moncton, New Brunswick; E. Kaminska, Hamilton, Ontario; A. Masetto, Sherbrooke, Quebec; E. Sutton, Halifax, Nova Scotia; J-P. Mathieu, Montreal, Quebec; M. Hudson, Montreal, Quebec; S. Ligier, Montreal, Quebec; T. Grodzicky, Montreal, Quebec; Carter Thorne, Newmarket, Ontario; S. LeClercq, Calgary, Alberta; M. Fritzler, Mitogen Advanced Diagnostics Laboratory, Calgary, Alberta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hudson, M., Steele, R., Canadian Scleroderma Research Group. et al. Immunosuppression for interstitial lung disease in systemic sclerosis – novel insights and opportunities for translational research. J. Cell Commun. Signal. 6, 187–190 (2012). https://doi.org/10.1007/s12079-012-0172-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12079-012-0172-4

Keywords

Search

Navigation